Microbot Medical signs three-year exclusive distribution deal with Medtechnica in Israel for LIBERTY system
Bitget2026/10/06 12:32Microbot Medical signed a three-year exclusive distribution deal with Medtechnica to market and sell the LIBERTY endovascular robotic system in Israel. Deal follows Israeli Ministry of Health AMAR clearance, with LIBERTY registered in the AMAR medical device registry in May 2026. Initial orders from Medtechnica are expected in Q4 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microbot Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-045866), on October 06, 2026, and is solely responsible for the information contained therein.
- Microbot Medical signed a three-year exclusive distribution deal with Medtechnica to market and sell the LIBERTY endovascular robotic system in Israel.
- Deal follows Israeli Ministry of Health AMAR clearance, with LIBERTY registered in the AMAR medical device registry in May 2026.
- Initial orders from Medtechnica are expected in Q4 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like

Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.

